	US 11,912,750 B2
	GDNF fusion polypeptides and methods of use thereof
Jasbir S. Seehra, Lexington, MA (US); and Jennifer Lachey, Lincoln, MA (US)
Assigned to Keros Therapeutics, Inc., Lexington, MA (US)
Appl. No. 16/348,982
Filed by Keros Therapeutics, Inc., Lexington, MA (US)
PCT Filed Nov. 9, 2017, PCT No. PCT/US2017/060953 § 371(c)(1), (2) Date May 10, 2019, PCT Pub. No. WO2018/089702, PCT Pub. Date May 17, 2018.
Claims priority of provisional application 62/420,480, filed on Nov. 10, 2016.
Prior Publication US 2019/0284251 A1, Sep. 19, 2019
Int. Cl. C07K 14/475 (2006.01); A61P 3/10 (2006.01); C07K 14/47 (2006.01); C07K 19/00 (2006.01); A61P 25/00 (2006.01); A61K 38/00 (2006.01); C07K 14/765 (2006.01); C07K 14/78 (2006.01); A61P 3/04 (2006.01)

CPC C07K 14/4756 (2013.01) [A61P 3/04 (2018.01); A61P 3/10 (2018.01); A61P 25/00 (2018.01); C07K 14/4702 (2013.01); C07K 14/475 (2013.01); C07K 14/765 (2013.01); C07K 14/78 (2013.01); C07K 19/00 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01); C07K 2319/31 (2013.01)]

19 Claims

1. A glial-derived neurotrophic factor (GDNF) fusion polypeptide consisting of the formula A-L-B, wherein

A is an Fc domain;

L is a linker; and

B has at least 95% sequence identity to a GDNF variant, wherein the sequence of the GDNF variant is (a) the sequence of amino acids 92-211 of SEQ ID NO: 1 or (b) a fragment of the sequence of amino acids 92-211 of SEQ ID NO: 1 amino acids 118-211 of SEQ ID NO: 1.